AffaMed in $103 Million Deal for Two Ocular Therapeutix Products

AffaMed Therapeutics of Shanghai announced a $103 million agreement to develop two Ocular Therapeutix products in Greater China. The products are Dextenza®, a treatment for postsurgical ocular inflammation and pain, and OTX-TIC, a treatment for elevated intraocular pressure of the eye. In 2019, AffaMed was formed by the CBC Group (formerly C-Bridge Capital), and two weeks ago, CBC merged EverInsight, a company specializing in CNS treatments, into AffaMed. More details.... Stock Symbol: (NSDQ: OCUL) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.